Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2021 Dec 13

PMID 34898561

Citations 2

Authors

Nai-Wen Kang

Kien-Thiam Tan

Chien-Feng Li

Yu-Hsuan Kuo

Affiliations

Soon will be listed here.

Abstract

Poorly differentiated pancreatic neuroendocrine carcinomas (NECs) are rare and aggressive malignancies with rapid disease progression and early widespread metastasis. Given histology similarity, they are commonly treated with platinum-based chemotherapy as small cell lung cancer (SCLC). However, no standard treatment has been established for recurrent or progressive disease. We present an Asian patient with recurrent poorly differentiated pancreatic NEC after curative surgery and adjuvant chemotherapy with cisplatin and etoposide. The tumor mutational burden (TMB) was high. The patient received chemotherapy combined with maintenance immunotherapy with nivolumab and achieved promising and durable response, suggesting TMB could be a biomarker to identify NEC patients for immune checkpoint inhibitor (ICI) treatment.

Citing Articles

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.

Raj N, Chan J, Wang S, Aggarwal R, Calabrese S, DeMore A Br J Cancer. 2023; 129(2):291-300.

PMID: 37208512 PMC: 10338510. DOI: 10.1038/s41416-023-02298-8.

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors.

Gubbi S, Vijayvergia N, Yu J, Klubo-Gwiezdzinska J, Koch C Horm Metab Res. 2022; 54(12):795-812.

PMID: 35878617 PMC: 9731788. DOI: 10.1055/a-1908-7790.

References

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View

Riaz N, Havel J, Kendall S, Makarov V, Walsh L, Desrichard A . Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nat Genet. 2016; 48(11):1327-1329. PMC: 5553281. DOI: 10.1038/ng.3677. View

Strickler J, Hanks B, Khasraw M . Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?. Clin Cancer Res. 2020; 27(5):1236-1241. PMC: 9912042. DOI: 10.1158/1078-0432.CCR-20-3054. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Eads J . Poorly Differentiated Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2015; 30(1):151-62. DOI: 10.1016/j.hoc.2015.09.007. View

Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K . Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011; 117(20):4617-22. DOI: 10.1002/cncr.26124. View

Mehnert J, Bergsland E, ONeil B, Santoro A, Schellens J, Cohen R . Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer. 2020; 126(13):3021-3030. DOI: 10.1002/cncr.32883. View

George S, Miao D, Demetri G, Adeegbe D, Rodig S, Shukla S . Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017; 46(2):197-204. PMC: 5408320. DOI: 10.1016/j.immuni.2017.02.001. View

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D . Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol. 2018; 36(7):633-641. PMC: 6075848. DOI: 10.1200/JCO.2017.75.3384. View

10.

Bracci L, Schiavoni G, Sistigu A, Belardelli F . Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2013; 21(1):15-25. PMC: 3857622. DOI: 10.1038/cdd.2013.67. View

11.

Wang V, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R . Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017; 5(1):75. PMC: 5604145. DOI: 10.1186/s40425-017-0281-y. View

12.

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

13.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

14.

Fesinmeyer M, Austin M, Li C, De Roos A, Bowen D . Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(7):1766-73. DOI: 10.1158/1055-9965.EPI-05-0120. View

15.

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

16.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

17.

Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M . FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012; 19(6):751-7. DOI: 10.1530/ERC-12-0002. View

18.

Koyama S, Akbay E, Li Y, Aref A, Skoulidis F, Herter-Sprie G . STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016; 76(5):999-1008. PMC: 4775354. DOI: 10.1158/0008-5472.CAN-15-1439. View

19.

Van Allen E, Miao D, Schilling B, Shukla S, Blank C, Zimmer L . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-211. PMC: 5054517. DOI: 10.1126/science.aad0095. View

20.

Ott P, Elez E, Hiret S, Kim D, Morosky A, Saraf S . Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017; 35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069. View